Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based biotechnology firm ProLynx has announced that the US Patent and Trademark Office has issued Patent 8,703,907 covering controlled release of drugs from dendrimer conjugates over prolonged periods.
Subscribe to our email newsletter
The recently issued patent, which is the second US patent issued to ProLynx, focuses on drugs covalently coupled via the company’s patented beta-eliminative linkers to multiple sites on a dendrimer.
According to the company, a dendrimer is a synthetic polymer characterized by repeated chain branching originating from a central core, giving rise to several chain endings available for drug attachment.
ProLynx co-founder and chief scientific officer Gary Ashley said dendrimers provide a potential improvement over standard PEGylation approaches, as they can carry a much higher drug payload.
"Together with our linkers, they offer slow release of a large amount of drug," Ashley said.
The company is focused on developing proprietary drug delivery systems (DDS) for half-life extension of proteins, peptides and small molecules.
ProLynx is seeking to apply its DDS to extend half-lives of drugs and drug candidates of pharmaceutical and biotechnology companies and also to out-license the long lasting drug conjugates in its pre-clinical product portfolio.